Brief: Cytodyn Receives Institutional Review Board Approval To Initiate Phase 2 Basket Trial For 22 Solid Tumor Cancers
21/02/2020 11:06
Feb 21 (Reuters) - Cytodyn Inc CYDY.PK :
* CYTODYN RECEIVES INSTITUTIONAL REVIEW BOARD APPROVAL TO
INITIATE
PHASE 2 BASKET TRIAL FOR 22 SOLID TUMOR CANCERS
Source text for Eikon: ID:nGNXTjgXG
Further company coverage: CYDY.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer